Neurology News

SEATTLE — Full recovery and functional independence is possible in patients who experience a disorder of consciousness after severe COVID-19 infection, according to a presenter at the 2022 American Academy of Neurology annual meeting.

SEATTLE — Sage Therapeutics will be starting a randomized, controlled trial in patients with Alzheimer’s disease, Aaron Koenig, MD, the company’s vice president of early clinical development, said at the 2022 American Academy of Neurology annual meeting.

SEATTLE — Sarah J. Spence, MD, PhD, shared tips on differentiating pediatric neurological conditions with overlapping symptoms, at the 2022 American Academy of Neurology annual meeting.

SEATTLE — Mobile stroke units were linked with improved outcomes compared with conventional emergency medical services for people with acute ischemic stroke, a presenter said at the 2022 American Academy of Neurology annual meeting.

SEATTLE — Self-administered home use of gamma sensory stimulation reduced brain atrophy safely in people with Alzheimer’s disease, a presenter said at the 2022 American Academy of Neurology annual meeting.

SEATTLE — People with persistent cognitive symptoms after mild COVID-19 infection had elevated cerebrospinal fluid inflammatory markers, according to a presentation at the 2022 American Academy of Neurology annual meeting.

SEATTLE — In a first-in-human study, participants with paralysis who received an endovascular brain-computer implant were able to effectively operate a computer, researchers reported at the American Academy of Neurology annual meeting.

A significant improvement of visual acuity was reported in eyes treated with a unilateral intravitreal injection of lenadogene nolparvovec for Leber hereditary optic neuropathy, researchers reported at the 2022 American Academy of Neurology annual meeting.

Quanterix Corp. announced it has partnered with the Alzheimer’s Drug Discovery Foundation to accelerate the development of a multi-analyte plasma test for early detection of Alzheimer’s disease.

Women who reported at least 2 months of antibiotic exposure in midlife experienced small decreases in cognition, which may be due to changes in the gut microbiome, data published in PLoS One showed.